

# Distribution and associated factors of hepatic iron – a population-based imaging study

Lisa Maier<sup>1,2,3</sup>, Ricarda von Krüchten<sup>4</sup>, Roberto Lorbeer<sup>5,6</sup>, Jule Filler<sup>1,2,3</sup>, Johanna Nattenmüller<sup>4,7</sup>, Barbara Thorand<sup>1,8</sup>, Wolfgang Koenig<sup>6,9,10</sup>, Wolfgang Rathmann<sup>8,11</sup>, Fabian Bamberg<sup>4</sup>, Christopher L. Schlett<sup>4</sup>, Annette Peters<sup>1,2,6,8</sup>, Susanne Rospleszcz<sup>1,2,6</sup>

1 Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany

2 Institute for Medical Information Processing, Biometry and Epidemiology – IBE, LMU Munich, Munich, Germany

3 Pettenkofer School of Public Health, Munich, Germany

4 Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Freiburg, Germany

5 Department of Radiology, University Hospital, LMU Munich, Munich, Germany

6 German Center for Cardiovascular Disease Research (DZHK), Munich, Germany

7 Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany

8 German Center for Diabetes Research (DZD), Neuherberg, Germany

9 German Heart Center Munich, Technical University Munich, Munich, Germany

10 Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany

11 Institute of Biometrics and Epidemiology, German Diabetes Center, Duesseldorf, Germany

**Short Title:** Distribution and associated factors of hepatic iron.

**Keywords:** hepatic iron, hepatic fat, magnetic resonance imaging, diabetes, markers.

**Correspondence and Reprint Requests:** Susanne Rospleszcz, Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany. Email: susanne.rosplezcz@helmholtz-muenchen.de.

**Grants and Fellowships:** This project has been financed in part through HGF Future Topic AMPro. The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universität, as part of LMUinnovativ. The KORA MRI sub-study received funding by the German Research Foundation (DFG, Deutsche Forschungsgemeinschaft, BA 4233/4–1, <http://www.dfg.de>), the Centre for Diabetes Research (DZD e.V., Neuherberg, Germany) and the German Centre for Cardiovascular Disease Research (Berlin, Germany, grants 81X2600209 and 81X2600214). The KORA-MRI sub-study was supported by an unrestricted research grant from Siemens Healthcare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Disclosure Summary:** The authors declare no conflict of interests.

# 1 **Abstract**

2 **Context:** Hepatic iron overload can cause severe organ damage. Therefore, an early  
3 diagnosis is crucial, and identification of modifiable risk factors could help to prevent  
4 manifestations of iron-driven complications.

5 **Objective:** To investigate the sex-specific distribution of hepatic iron content (HIC) in a  
6 population-based sample, and to identify relevant associated factors from a panel of markers.

7 **Methods:** We analysed N=353 participants from a cross-sectional, population-based cohort  
8 in Southern Germany (KORA FF4) who underwent whole-body magnetic resonance imaging.  
9 HIC was assessed by single-voxel spectroscopy with a high-speed T2-corrected multi-echo  
10 technique. A large panel of markers, including anthropometric, genetic and laboratory values  
11 as well as behavioural risk factors were assessed. Relevant factors associated with HIC were  
12 identified by variable selection based on LASSO regression with bootstrap resampling.

13 **Results:** HIC in the study sample (mean age at examination was 56.0 years, 58.4% were  
14 men) was significantly lower in women (mean±SD: 39.2±4.1 s<sup>-1</sup>) than in men (41.8±4.7 s<sup>-1</sup>,  
15 p<0.001). Relevant factors associated with HIC were HbA1c and prediabetes for men, and  
16 visceral adipose tissue and age for women. Hepatic fat, alcohol consumption, and a genetic  
17 risk score for iron levels were associated with HIC in both sexes.

18 **Conclusion:** There are sex-specific associations of HIC with markers of body composition,  
19 glucose metabolism and alcohol consumption.

## 20 **Introduction**

21 Iron is an essential element in human organisms. It is of great importance for the transport  
22 and storage of oxygen, but also regulates cell survival and DNA synthesis.

23 Consequently, deviations from normal ranges of stored body iron are associated with the  
24 development of certain pathologies. Excess in body iron storage leads to potential cell damage  
25 due to the generation of reactive oxygen species (ROS). These highly reactive oxygens induce  
26 lipid peroxidation and DNA damage resulting, among others, in liver injuries (1).

27 In particular, the liver plays an important role in maintaining iron homeostasis. Hepcidin, a  
28 protein regulated by the HAMP gene and expressed within the liver, is the main regulator of  
29 iron homeostasis. Its expression is stimulated in the presence of iron overload to inhibit the  
30 resorption of iron. Moreover, the liver is the main storage site of iron and is susceptible to iron  
31 overload due to iron accumulation in hepatocytes (2). Hepatic iron content (HIC) serves as a  
32 surrogate for whole-body iron storage (3). Excessive hepatic iron storage can progress to  
33 severe liver diseases, such as fibrosis, cirrhosis, or hepatocellular carcinoma (4).

34 Mechanisms responsible for the disruption of iron homeostasis and pathways associated with  
35 comorbidities are still insufficiently explored. However, studies have linked increased HIC with  
36 type 2 diabetes mellitus (T2DM) and insulin resistance (5), hypertension (6), and non-alcoholic  
37 fatty liver disease (NAFLD) (2) suggesting a cross-talk between metabolic syndrome (MetS)  
38 and iron metabolism.

39 HIC increases gradually to pathological levels (7). Therefore, an early diagnosis of elevated  
40 HIC and identification of relevant, potentially modifiable risk factors would be beneficial to  
41 prevent manifestations of iron-driven organ damage and further complications.

42 However, clinical assessment of HIC is challenging. Early presentations of hepatic iron  
43 overload range from asymptomatic to mild cases or patients presenting with predominantly  
44 non-specific symptoms (8). Population-based studies are scarce since liver biopsy, the gold  
45 standard for HIC assessment, is an invasive procedure and not feasible at a population level.  
46 Hence, the majority of studies on HIC are based on small patient cohorts (9, 10). Alternatively,

47 serum ferritin is regularly assessed as an indirect marker for body iron stores. Several  
48 population-based studies have already been conducted analysing associations of serum  
49 ferritin with metabolic disorders (11, 12). However, the interpretability of this biomarker is  
50 limited, as serum ferritin is also influenced by inflammation and coexisting liver diseases, and  
51 therefore might be artificially elevated (13).

52 Magnetic resonance imaging (MRI) has evolved as a powerful non-invasive diagnostic tool to  
53 accurately assess HIC. Nonetheless, only few studies have so far investigated the distribution  
54 of HIC in population-based samples and reported early evidence on a limited number of  
55 associated factors (14, 15).

56 Therefore, we aim to determine the sex-specific distribution of MRI-derived HIC in a  
57 population-based study, and to identify relevant associated factors from a broad panel of  
58 markers.

## 59 **Materials and Methods**

### 60 **Study Design and Participants**

61 The study sample consists of participants from the cross-sectional KORA MRI study (KORA:  
62 “Cooperative Health Research in the Region of Augsburg”), nested within the KORA FF4 study  
63 (N=2279, enrolled between 2013-2014). KORA FF4 is the second follow-up of the population-  
64 based KORA S4 cohort (N=4261, enrolled between 1999-2001). Overall, study design,  
65 recruitment and data collection of the KORA studies have been described in detail elsewhere  
66 (16). The KORA MRI sub-study includes 400 participants who underwent whole-body MRI,  
67 with a focus on assessing subclinical cardiometabolic diseases at different stages of impaired  
68 glucose metabolism (17). Briefly, participants with a history of cardiovascular disease, older  
69 than 73 years, or with any contraindications to whole-body MRI were excluded. For the current  
70 analysis, a total of 47 participants had to be excluded due to missing hepatic iron  
71 measurements or covariables, yielding a final main sample size of 353 participants. The  
72 detailed participant flow is shown in Figure 1.

73 The study was approved by the ethics committee of the Ludwig-Maximilians-University Munich  
74 and the Bavarian Chamber of Physicians. It was performed according to the Declaration of  
75 Helsinki and all participants gave written informed consent.

## 76 Outcome and Exposure Assessment

### 77 ***MRI examination: Hepatic iron and fat content***

78 MRI examinations were performed on a 3 Tesla MRI scanner (Magnetom Skyra; Siemens AG,  
79 Siemens Healthineers, Erlangen, Germany). The protocol comprised dedicated sequences for  
80 the respective body regions, as detailed elsewhere (17). HIC was measured in the right and  
81 left hepatic lobe (segments VII and II, respectively) using a single-voxel spectroscopy with a  
82 high-speed T2-corrected multi-echo (HISTO) technique, allowing for the simultaneous  
83 assessment of hepatic iron and hepatic fat (18). Hepatic fat was obtained as hepatic fat  
84 fraction (HFF) in percent and averaged over the left and right liver lobe. HIC was quantified as  
85 relaxation rate  $1/T2^*$  in  $s^{-1}$  in the left and right liver lobe. The arithmetic mean of left and right  
86 lobe constitutes the main outcome of the present analysis.

### 87 ***Covariates***

88 A set of health-related covariables was collected from all KORA FF4 participants at the study  
89 center in a standardized fashion. Briefly, the assessment comprised laboratory values,  
90 anthropometric measurements, information about medication intake, sociodemographic  
91 characteristics and health behaviour (e.g. smoking, physical activity). Data were collected and  
92 maintained by trained staff according to standardized protocols. A venous blood sample in  
93 fasted condition was drawn from each participant to determine laboratory values. The  
94 laboratory analysis included a standard complete blood count, blood lipids, glucose  
95 metabolism markers, renal function parameters, an electrolyte panel, and liver enzymes.  
96 Further information is detailed in Supplementary Table 1. Since 2-hour insulin and 2-hour  
97 glucose data were only available for participants without established T2DM, sensitivity  
98 analyses including these variables were performed on a smaller sample without participants  
99 with diagnosed T2DM.

100 Furthermore, visceral and subcutaneous adipose tissue (VAT and SAT) were measured by  
101 MRI using a three-dimensional in/opposed-phase VIBE-Dixon sequence from the femoral  
102 head to the diaphragm and cardiac apex, respectively. VAT and SAT were post-processed  
103 using an automated algorithm-driven procedure for segmentation (19) and are given in liter (l).  
104 Genotyping was done with the Affymetrix Axiom Chip (20) and subsequent imputation was  
105 based on the Haplotype Reference Consortium (HRC) imputation panel r1.1 , resulting in post-  
106 imputation probabilities (dosages) per allele. A genetic risk score was calculated to estimate  
107 the combined effect of selected single-nucleotide polymorphisms (SNPs) on HIC. Relevant  
108 SNPs associated with markers of iron metabolism were identified by querying the GWAS  
109 Catalogue (<https://www.ebi.ac.uk/gwas/>).  
110 SNPs were then weighted by coefficients from sex-stratified univariate linear regressions  
111 against HIC (Supplementary Table 2), multiplied by the respective allele dosage, and summed  
112 up.

## 113 Statistical Analysis

114 Descriptive statistics for continuous variables are presented as either arithmetic mean and  
115 standard deviation (SD) or median and interquartile range (IQR), where appropriate, and as  
116 counts and percentages for categorical variables. Differences between male and female  
117 participants were tested using t-test, Mann-Whitney-U test or  $\chi^2$  -test, respectively.  
118 Correlations between HIC and continuous exposure variables were determined by  
119 Spearman's rho correlation coefficient and corresponding p-values. Additionally, participants  
120 were classified according to presence of hepatic steatosis defined by a cutoff of HFF  $\geq$  5.6 %  
121 (21). All analyses were stratified by sex.

122 To identify relevant factors associated with HIC, least absolute shrinkage and selection  
123 operator (LASSO) linear regression was performed. LASSO is particularly suitable for this  
124 exploratory study, as it constitutes a variable selection method able to extract the most strongly  
125 associated factors from a large set of potentially correlated variables (22). LASSO achieves  
126 variable selection by applying a regularization process, where regression coefficients of less

127 associated variables are shrunk towards zero by adding a penalty term  $\lambda$ . To quantify the  
128 relative importance of the selected variables and assess model stability, 1000 bootstrap  
129 samples were generated, and the LASSO regression model was fitted on each bootstrap  
130 sample. The penalty term  $\lambda$  was optimized for each bootstrap sample via 10-fold cross-  
131 validation. The percentage of variable inclusion among the 1000 bootstrap samples was  
132 calculated to quantify the relative importance of each variable, and variables with inclusion  
133 frequencies  $> 20\%$  were considered relevant (23). Due to the regularization procedure,  
134 LASSO coefficients are biased towards zero. Therefore, calculation of confidence intervals  
135 and p-values is not straightforward.

136 To assess the strength of associations between covariables and HIC, unpenalized linear  
137 regression analyses adjusted for age and HFF were applied for every variable selected in  
138 LASSO regression. Results from unpenalized regression analyses are reported as  
139 unstandardized beta coefficients with corresponding confidence intervals, p-values and  
140 adjusted  $R^2$ . Variables with a highly skewed distribution were log-transformed before  
141 regression analyses.

142 To further assess model stability, both penalized LASSO regressions and unpenalized  
143 regressions were run excluding HFF as a covariate.

144 In this exploratory analysis, p-values were not corrected for multiple testing and values less  
145 than 0.05 were considered to indicate statistical significance. All analyses were performed  
146 using R version 3.6.1.

## 147 **Results**

### 148 **Study sample**

149 Characteristics of the study sample are provided in Table 1. Age at the time of examination  
150 was  $56.0 \pm 9.1$  (mean  $\pm$  SD) years, 58.4% were male. Among the 353 participants, 12.2% had  
151 diagnosed diabetes, 23.5% had prediabetes and 64.3% were normoglycemic. Men had  
152 significantly higher values of HFF than women (median (IQR): 7.02% (10.08) and 3.53%  
153 (4.28),  $p < 0.001$ , respectively).

154 Mean laboratory values were within the non-pathological range (for reference ranges, see  
155 Supplementary Table 3). For example, liver enzymes were within normal ranges for both men  
156 and women (GGT: men 35.3 U/l, women: 19.6 U/l; AST: men 24.5 U/l, women: 20.0 U/l; ALT:  
157 men 31.0 U/l, women 21.0 U/l).

## 158 Distribution of HIC and Correlation with Age, HFF and Genetic Risk 159 Score

160 HIC was significantly higher in men than in women ( $41.8 \text{ s}^{-1} \pm 4.7$  and  $39.2 \text{ s}^{-1} \pm 4.1$ ,  $p < 0.001$   
161 respectively). The distribution was approximately normal. Applying the cut-off value of  $R^2 >$   
162  $41 \text{ s}^{-1}$  defined by Kühn et al. (14). 44.5% of the participants would be diagnosed with mild  
163 hepatic iron overload. However, no participant had moderate to severe iron overload (cutoffs  
164  $62.5 \text{ s}^{-1}$  and  $70.1 \text{ s}^{-1}$ , respectively). Age was significantly correlated with HIC in women  
165 ( $\rho=0.48$ ,  $p < 0.001$ ) but not in men ( $\rho=0.11$ ,  $p=0.13$ , see Figure 2). HFF was correlated with  
166 HIC in both men and women ( $\rho=0.32$ ,  $p < 0.001$ , and  $\rho=0.51$ ,  $p < 0.001$ , respectively, see  
167 Figure 2).

168 Using a cutoff of  $\text{HFF} \geq 5.6\%$ , 129 men (62.6%) and 44 women (29.9%) had hepatic steatosis.  
169 HIC was higher in individuals with hepatic steatosis compared to those without (men:  $42.8 \text{ s}^{-1}$   
170 vs  $40.0 \text{ s}^{-1}$ ,  $p < 0.001$ , women:  $41.7 \text{ s}^{-1}$  vs  $38.1 \text{ s}^{-1}$ ,  $p < 0.001$ ) (Supplementary Figure 1).

171 HIC increased with quartiles of the genetic risk score (Figure 3), resulting in significant  
172 differences in HIC between the lowest and highest quartile (men:  $40.6 \text{ s}^{-1}$  vs  $43.1 \text{ s}^{-1}$ ,  $p=0.007$ ,  
173 women:  $37.7 \text{ s}^{-1}$  vs  $40.2 \text{ s}^{-1}$ ,  $p=0.03$ ).

## 174 Identification of Relevant Associated Variables

175 Relevant factors associated with HIC identified by LASSO regression are depicted in Figure  
176 4. For men, most frequently selected variables were HFF, HbA1c and prediabetes, whereas  
177 for women, most frequently selected variables were age, HFF and VAT. Alcohol consumption  
178 was selected in both men and women. When excluding HFF from the analysis, results were  
179 mainly stable. Further selected parameters included fasting insulin, uric acid, triglycerides,  
180 vitamin D and beta-blocker use (Supplementary Figure 2).



181 In a sensitivity analysis including only participants who underwent an OGTT (N=323), results  
182 remained largely stable, but 2-hour glucose and 2-hour insulin were additionally selected as  
183 relevant covariates (Supplementary Figures 3, 4).

184 In the genetic analyses, selected variables also remained mostly the same (Figure 5).  
185 Leucocytes were further selected for both sexes and the genetic risk score was among the  
186 most frequently selected variables.

## 187 **Strength of Effects**

188 Table 2 and 3 show the results of unpenalized linear regression analyses with and without  
189 adjustment for HFF for all variables that were identified in LASSO regression.

190 In general, associations attenuated after adjustment for HFF. Variance of outcome explained  
191 (adjusted  $R^2$ ) was generally higher in women (21-39%) than in men (2-14%).

192 In men, of all variables identified by LASSO regression HFF, HbA1c, urine albumin, alcohol  
193 consumption, ACE inhibitors, and diuretics were also significantly associated with HIC in  
194 unpenalized regression. Higher values of HbA1c were negatively associated with HIC ( $\beta=-$   
195 1.44,  $p<0.001$ ), whereas higher consumption of alcohol was associated with increased HIC  
196 ( $\beta=0.02$ ,  $p=0.04$ ). Urine albumin and diuretics showed a negative relationship with HIC  
197 ( $\beta=-0.80$ ,  $p<0.01$  and  $\beta=-2.50$ ,  $p=0.01$ , respectively).

198 In women, age, HFF, potassium, alcohol consumption, and calcium antagonists were also  
199 significantly associated with HIC in unpenalized regression. We revealed a negative  
200 relationship between HIC and potassium and calcium antagonist intake, respectively ( $\beta=-2.74$ ,  
201  $p=0.03$  and  $\beta=-2.24$ ,  $p=0.03$ ). Alcohol consumption was also associated with increased HIC  
202 ( $\beta=0.05$ ,  $p<0.01$ ).

203 The continuous genetic risk score was positively associated with HIC in both men and women  
204 ( $\beta=0.64$ ,  $p<0.01$  and  $\beta=0.65$ ,  $p<0.01$ , respectively).

## 205 **Discussion**

206 In this explorative study, we investigated sex-specific distributions of HIC in a population-  
207 based sample and identified associated factors from a large panel of markers. Overall, HIC

208 was normally distributed with significantly lower values in women and none of the participants  
209 exceeds the threshold for severe hepatic iron overload. We revealed notable sex-specific  
210 associations of HIC with markers of body composition, glucose metabolism and alcohol  
211 consumption.

## 212 Distribution of HIC and Effect of Age

213 The distribution of HIC in our sample was comparable to other studies. Kühn et al. (14)  
214 reported median HIC values of  $34.4 \text{ s}^{-1}$  and the UK Biobank (15) found mean values of  $44.02$   
215  $\text{s}^{-1}$  compared to our  $40.7 \text{ s}^{-1}$ . Kühn et al.'s cutoff suggested that 44.5% of the participants of  
216 the current study present mild iron overload. As expected, this is a higher prevalence than  
217 found by Kühn et al. (17.4%) and a slightly lower prevalence than in the UK Biobank study  
218 (51.5%). We found higher values of HIC in men compared to women, which is coherent with  
219 the aforementioned studies (14, 15). Higher levels of HIC in men might be explained by higher  
220 levels of testosterone since androgens are known to be regulators of hepcidin expression (24).  
221 Besides, men had higher HFF levels than women, and HFF is substantially associated with  
222 HIC, as outlined below. Moreover, most women before onset of menopause regularly excrete  
223 iron through menstrual bleeding, leading to generally lower body iron. We found a strong  
224 correlation between age and HIC in women, suggesting a link to the onset of menopause. Our  
225 findings regarding the effect of age on HIC are supported by the study of Obrzut et al. (25),  
226 who examined considerably younger participants and reported distinctly lower HIC levels  
227 (mean:  $28.7 \text{ s}^{-1}$ ).

## 228 Body Composition and Blood Lipid Markers

229 We identified HFF as a main associated factor with HIC. This is in line with results from the  
230 UK Biobank (15) and MRI studies on patient samples (26, 7). In our study, the association  
231 was stronger in women than in men.

232 Furthermore, our results demonstrated that VAT is associated with HIC in women. This may  
233 be explained by the fact that the iron-regulating hormone hepcidin is expressed in abdominal

234 adipose tissue, in addition to the liver which is the main site of synthesis (27). Consequently,  
235 higher amounts of adipose tissue stimulate the HAMP gene and increase hepcidin production.  
236 This pathway is independent of diabetes status (27), which might explain the stability of VAT  
237 as an associated factor with HIC among all analyses.

238 Our procedure selected triglycerides as a relevant factor for both sexes. This finding is  
239 supported by the observation of Jehn et al. (28), who reported a significant increase in serum  
240 ferritin with increasing triglyceride levels. In addition, a study including only participants with  
241 iron overload due to hemochromatosis reported elevated triglyceride levels as well (29).  
242 Related to this finding is the selection of lipid-lowering agents in women, which might serve as  
243 a proxy for underlying hypertriglyceridemia in this context.

244 In summary, our results indicate a relationship between abdominal adipose tissue and lipid  
245 profile with hepatic iron storage. This relationship is more pronounced in women.

## 246 Genetic Effects

247 The genetic risk score was frequently selected as a relevant associated factor with HIC.  
248 Weights of the respective SNPs were notably different between men and women  
249 (Supplementary Table 2), indicating sex-specific effects. Genetic variants rs1799945 and  
250 rs1800562 in HFE showed the strongest association with HIC in men and women,  
251 respectively. Both SNPs lead to hepatic iron overload due to decreased hepcidin levels (30,  
252 31) and are additionally associated with ferritin and transferrin (32, 33). Moreover, variants  
253 rs855791 and rs4820268 in TMPRSS6 are known to be associated with iron traits including  
254 transferrin, serum iron and ferritin (34, 30), since TMPRSS6 modulates the transcription of  
255 hepcidin (34). A mendelian randomization study analysing UK Biobank data revealed a causal  
256 relationship between central obesity and elevated HIC (30). It is hypothesized that an interplay  
257 between genetics and dietary factors and a cross-talk between liver and adipose tissue is  
258 responsible for the causal effect of abdominal obesity on HIC.

## 259 Markers of Glucose Metabolism

260 Several diabetes-related markers were selected to be associated with HIC, even after  
261 exclusion of participants with established T2DM. We found an association with HIC for  
262 prediabetes and HbA1c in men, which is in line with Britton et al. (9) who found an inverse  
263 correlation between HIC and HbA1c. On the other hand, Kühn et al. (14) reported that HbA1c  
264 was not a relevant predictor of iron overload in their study. Recent findings from a subcohort  
265 of the aforementioned study showed a stronger association between serum ferritin and T2DM  
266 and an altered glucose metabolism even in the absence of pathologic iron overload,  
267 suggesting a combined effect of hepatic iron overload and ferritin (35). The relationship  
268 between prediabetes and increased HIC is consistent with other studies, analysing the  
269 association of diabetes status and serum ferritin levels (36, 12).

270 Our results regarding fasting glucose and HIC are conflicting since we found a positive  
271 association between HIC and fasting glucose in women but a negative association in men,  
272 whereas 2-hour glucose showed a positive association only in men. Animal studies showed  
273 an increase in blood glucose levels in animals with iron overload, indicating that increased iron  
274 storage might be associated with altered glucose metabolism (37). A mendelian randomization  
275 study analysing UK Biobank data revealed a potentially causal association of fasting glucose  
276 with increased HIC (30).

277 An association between iron and diabetes risk in hereditary iron metabolism disorders such  
278 as hemochromatosis is already established (38). Even nonpathologically increased body iron  
279 stores are related with higher risks for development of T2DM (37). Haap et al. (39) found a  
280 positive association between HIC with T2DM and insulin resistance. Moreover, dysmetabolic  
281 iron overload syndrome (DIOS), defined as the presence of iron overload and insulin  
282 resistance, is frequently observed in patients with MetS (37). Consequently, there seems to  
283 be an association between insulin-resistance syndrome and iron overload (12). Increased  
284 ROS are observed in iron deficiency as well as iron overload syndromes and ROS are known  
285 to induce beta cell damage and insulin resistance (1). An overactivation of gluconeogenesis

286 leading to increased hepcidin expression is discussed as a pathway, leading to iron  
287 accumulation and cell damage within the liver. This indicates an interplay between hepatic  
288 dysfunction, serum ferritin and metabolic disorders. Our results therefore confirm and expand  
289 previous findings regarding the association of markers of glucose metabolism with HIC.

## 290 Alcohol Consumption

291 The link between alcohol consumption and HFF is already established (40). Our results also  
292 show that a higher consumption of alcohol is associated with increased HIC, independent of  
293 HFF. These results are consistent with Whitfield et al. (41) who reported that even moderate  
294 alcohol consumption raises body iron stores. Furthermore, patients with alcoholic liver disease  
295 have been found to show alcohol induced suppression of hepcidin. Alcohol induces hypoxia,  
296 which is known to reduce the expression of hepatic HAMP leading to decreased hepcidin  
297 levels (42).

## 298 Renal Function Parameters and Diuretics

299 The data-driven approach revealed uric acid as a relevant associated factor with HIC in men  
300 and women. Previous studies including healthy adults, reported a positive correlation between  
301 serum ferritin and uric acid independent of gender and age (43). Furthermore, another study  
302 reported a worsening of hepatic and renal functioning when a simultaneous elevation in uric  
303 acid and serum ferritin levels were present (44). Potential mechanisms of the association  
304 between iron overload with increased uric acid could be related to oxidative stress or insulin  
305 sensitivity. Additionally, our group previously found an association between increased uric acid  
306 and HFF (45).

307 Contrary to formerly reported positive relations between serum ferritin and proteinuria (46), we  
308 found a negative association between HIC and urine albumin in men when including  
309 participants with established diabetes in the analysis. The results might differ due to the  
310 heterogeneous study populations, since Kim et al. (46) excluded patients with diabetes from  
311 the analyses.

312 We found that diuretic use was associated with lower HIC with relatively large effect sizes.  
313 Diuretics are frequently prescribed in patients with renal diseases and one study described a  
314 high proportion of anaemia in haemodialysis patients, which in turn was associated with  
315 increased inflammatory status (47). Systemic inflammation leads to an upregulation of signal  
316 transducers and activators of transcription 3 (STAT3) and increases the synthesis of hepcidin  
317 followed by decrease in iron levels (48). This pathway is as a possible explanation for our  
318 findings, indicating a role of renal function markers in liver iron storage.

### 319 Complete Blood Count

320 Selection of erythrocytes as a relevant variable was stable among the different models for both  
321 sexes, relating increased levels of erythrocytes with decreased HIC. We speculate that an  
322 increase in erythrocyte levels mirrors the expansion of erythropoiesis due to an increased iron  
323 demand within the body. To sufficiently cover the demand, hepcidin expression is suppressed  
324 and iron stored within the liver is released (49). Interestingly, haemoglobin, the iron containing  
325 protein in erythrocytes, and haematocrit, were not among the selected variables associated  
326 with HIC in our study, whereas Kühn et al. (14) revealed mean corpuscular haemoglobin as  
327 the most predictive marker for HIC. Additionally, we demonstrated that the selection of  
328 thrombocytes was more frequent among women compared to men. Thrombocytopenia is  
329 associated with iron deficiency due to the increased risk for haemorrhages and another study  
330 reports a correlation between HIC and thrombocytes in patients with transfusion-related iron  
331 overload (50).

### 332 Electrolyte Panel and Medication

333 We identified potassium as a relevant marker in women associated with a decrease in HIC.  
334 Given that iron overload is associated with T2DM, this relationship is plausible since  
335 hypokalaemia is associated with an increased risk for T2DM due to reduced insulin sensitivity  
336 (51). However, diuretic use can also affect potassium balance and, as mentioned above,  
337 diuretic use was also found to be associated with HIC.

338 Additionally, we observed a negative association between sodium and HIC in women.  
339 Hyponatremia is frequently observed in cirrhotic patients and decreased serum levels  
340 correlate with severity of cirrhosis (52). Our results indicate that this association might already  
341 be visible in the non-pathological range.

342 Use of cardiovascular medication (ACE inhibitors in men, calcium antagonists in women) was  
343 found to be relevantly associated with decreased HIC. Associations of cardiovascular  
344 medication with serum ferritin have already been suggested (53) but conclusive findings about  
345 the effect of antihypertensive medication on iron metabolism are lacking. Results from animal  
346 studies suggest that a decrease in divalent metal transporter-1 (DMT-1) expression due to  
347 calcium antagonists may be responsible for a reduction in iron absorption (54).

## 348 **Strength and Limitations**

349 Our study has unique strengths. The study sample from an established population-based  
350 cohort was well characterized which enabled the analysis of a rich set of markers and risk  
351 factors. The assessment of HIC by MRI allowed for a precise quantification of both hepatic  
352 iron and fat content. Moreover, we applied appropriate statistical techniques to identify  
353 relevant associated factors and ensured robustness and stability of our findings.

354 Nevertheless, our study has several limitations which need to be addressed. Most importantly,  
355 we lacked data of serum indices of iron metabolism, such as ferritin and hepcidin. Further  
356 research on disentangling the association of circulating iron markers and markers of iron  
357 storage is necessary. Moreover, the available data set was limited to a relatively small size.  
358 Therefore, replication and extension of our findings in larger population-based cohorts are  
359 needed. One opportunity is the German National Cohort, a population-based study within  
360 Germany with MRI data on 30000 participants, which would enable more intricate analyses  
361 with higher statistical power.

## 362 **Conclusion**

363 Our results indicate sex-specific associations of MRI-derived HIC with several factors,  
364 specifically markers of glucose metabolism, renal function, body composition, alcohol intake

365 and genetic markers. Thus, our study extends previous knowledge of relevant HIC-related  
366 factors to a population-based sample. Further work is required to disentangle the complexity  
367 of pathways between disorders of iron homeostasis and pathologies.



## Acknowledgements

The authors are grateful for the participants who volunteered to provide the data. We thank the field workers, radiologists, interviewers, technicians, and computer assistants for their contributions to the collection of data.

**Author Contributions:** LM performed the statistical analyses, evaluated the results and drafted the manuscript. FB and AP conceived and designed the KORA-MRI study. RvK, JN, FB and CLS collected the MRI data and analyzed the images. RvK, RL, JN, FB and CLS contributed substantially to MRI data preparation and quality assurance. BT, WK, WR and AP contributed substantially to the collection, quality assurance and data preparation of the biomarker measurements within KORA. RvK, RL, JF, JN, BT, WK, WR, FB, CLS, and AP contributed substantially to the scientific content and interpretation of the results. SR conceived the study question, contributed to the statistical analyses, the interpretation of the results and the drafting of the manuscript. SR had primary responsibility for final content. All authors read and approved the final manuscript.

## Data Availability

Restrictions apply to the availability of some or all data generated or analysed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

## References

1. Fleming RE, Ponka P Iron overload in human disease, *N Engl J Med*. 2012; 366:348–359
2. Pietrangelo A Iron and the liver, *Liver Int*. 2016; 36 Suppl 1:116–123
3. Hernando D, Levin YS, Sirlin CB, Reeder SB Quantification of liver iron with MRI: state of the art and remaining challenges, *J Magn Reson Imaging*. 2014; 40:1003–1021
4. Mehta KJ, Farnaud SJ, Sharp PA Iron and liver fibrosis: Mechanistic and clinical aspects, *World J Gastroenterol*. 2019; 25:521–538
5. Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, Le Gall JY, Brissot P, David V, Deugnier Y Insulin resistance-associated hepatic iron overload, *Gastroenterology*. 1999; 117:1155–1163
6. Seravalle G, Dell'Oro R, Quarti-Trevano F, Spaziani D, Bertoli S, Airoidi F, Mancina G, Grassi G Sympathetic Overactivation in Patients With Essential Hypertension and Hepatic Iron Overload, *Hypertension*. 2020; 76:1444–1450
7. Karlsson M, Ekstedt M, Dahlström N, Forsgren MF, Ignatova S, Norén B, Dahlqvist Leinhard O, Kechagias S, Lundberg P Liver R2\* is affected by both iron and fat: A dual biopsy-validated study of chronic liver disease, *J Magn Reson Imaging*. 2019; 50:325–333
8. Radford-Smith DE, Powell EE, Powell LW Haemochromatosis: a clinical update for the practising physician, *Intern Med J*. 2018; 48:509–516
9. Britton L, Bridle K, Reiling J, Santrampurwala N, Wockner L, Ching H, Stuart K, Subramaniam VN, Jeffrey G, St Pierre T, House M, Gummer J, Trengove R, Olynyk J, Crawford D, Adams L Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease, *Hepatol Commun*. 2018; 2:644–653
10. Castiella A, Urreta I, Zapata E, Zubiaurre L, Alústiza JM, Otazua P, Salvador E, Letamendi G, Arrizabalaga B, Rincón ML, Emparanza JI Liver iron concentration in dysmetabolic hyperferritinemia: Results from a prospective cohort of 276 patients, *Ann Hepatol*. 2020; 19:31–35
11. Liu Y, Song J, Tian H, Chen T, Gao Y, Yu H, Zhang X, Ren Y Association of serum ferritin concentrations with prevalence of prediabetes, type 2 diabetes mellitus, and metabolic syndrome in a Chinese population from Sichuan, *International Journal of Diabetes in Developing Countries*. 2015; 35:522–528
12. Wrede CE, Buettner R, Bollheimer LC, Schölmerich J, Palitzsch K-D, Hellerbrand C Association between serum ferritin and the insulin resistance syndrome in a representative population, *Eur J Endocrinol*. 2006; 154:333–340
13. Daru J, Colman K, Stanworth SJ, La Salle B de, Wood EM, Pasricha S-R Serum ferritin as an indicator of iron status: what do we need to know?, *Am J Clin Nutr*. 2017; 106:1634S-1639S
14. Kühn J-P, Meffert P, Heske C, Kromrey M-L, Schmidt CO, Mensel B, Völzke H, Lerch MM, Hernando D, Mayerle J, Reeder SB Prevalence of Fatty Liver Disease and Hepatic Iron Overload in a Northeastern German Population by Using Quantitative MR Imaging, *Radiology*. 2017; 284:706–716
15. McKay A, Wilman HR, Dennis A, Kelly M, Gyngell ML, Neubauer S, Bell JD, Banerjee R, Thomas EL Measurement of liver iron by magnetic resonance imaging in the UK Biobank population, *PLoS ONE*. 2018; 13:e0209340
16. Holle R, Happich M, Löwel H, Wichmann HE KORA--a research platform for population based health research, *Gesundheitswesen*. 2005; 67 Suppl 1:S19-25
17. Bamberg F, Hetterich H, Rospleszcz S, Lorbeer R, Auweter SD, Schlett CL, Schafnitzel A, Bayerl C, Schindler A, Saam T, Müller-Peltzer K, Sommer W, Zitzelsberger T, Machann J, Ingrisich M, Selder S, Rathmann W, Heier M, Linkohr B, Meisinger C, Weber C, Ertl-Wagner B, Massberg S, Reiser MF, Peters A Subclinical Disease Burden as Assessed by Whole-Body MRI in Subjects With Prediabetes, Subjects With Diabetes, and Normal Control Subjects From the General Population: The KORA-MRI Study, *Diabetes*. 2017; 66:158–169

18. Hetterich H, Bayerl C, Peters A, Heier M, Linkohr B, Meisinger C, Auweter S, Kannengießer SAR, Kramer H, Ertl-Wagner B, Bamberg F Feasibility of a three-step magnetic resonance imaging approach for the assessment of hepatic steatosis in an asymptomatic study population, *Eur Radiol.* 2016; 26:1895–1904
19. Storz C, Heber SD, Rospleszcz S, Machann J, Sellner S, Nikolaou K, Lorbeer R, Gatidis S, Elser S, Peters A, Schlett CL, Bamberg F The role of visceral and subcutaneous adipose tissue measurements and their ratio by magnetic resonance imaging in subjects with prediabetes, diabetes and healthy controls from a general population without cardiovascular disease, *Br J Radiol.* 2018; 91:20170808
20. Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, Sarwath H, Thareja G, Wahl A, DeLisle RK, Gold L, Pezer M, Lauc G, El-Din Selim MA, Mook-Kanamori DO, Al-Dous EK, Mohamoud YA, Malek J, Strauch K, Grallert H, Peters A, Kastenmüller G, Gieger C, Graumann J Connecting genetic risk to disease end points through the human blood plasma proteome, *Nat Commun.* 2017; 8:14357
21. Schaapman JJ, Tushuizen ME, Coenraad MJ, Lamb HJ Multiparametric MRI in Patients With Nonalcoholic Fatty Liver Disease, *J Magn Reson Imaging.* 2021; 53:1623–1631
22. Tibshirani R Regression Shrinkage and Selection Via the Lasso, *Journal of the Royal Statistical Society: Series B (Methodological).* 1996; 58:267–288
23. Bin R de, Janitza S, Sauerbrei W, Boulesteix A-L Subsampling versus bootstrapping in resampling-based model selection for multivariable regression, *Biometrics.* 2016; 72:272–280
24. Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S, Chan SY, Serra C, Jasuja R, Travison TG, Muckenthaler MU, Nemeth E, Bhasin S Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells, *Aging Cell.* 2013; 12:280–291
25. Obrzut M, Atamaniuk V, Glaser KJ, Chen J, Ehman RL, Obrzut B, Cholewa M, Gutkowski K Value of liver iron concentration in healthy volunteers assessed by MRI, *Sci Rep.* 2020; 10:17887
26. Bashir MR, Wolfson T, Gamst AC, Fowler KJ, Ohliger M, Shah SN, Alazraki A, Trout AT, Behling C, Allende DS, Loomba R, Sanyal A, Schwimmer J, Lavine JE, Shen W, Tonascia J, van Natta ML, Mamidipalli A, Hooker J, Kowdley KV, Middleton MS, Sirlin CB Hepatic R2\* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease, *J Magn Reson Imaging.* 2019; 49:1456–1466
27. Bekri S, Gual P, Anty R, Luciani N, Dahman M, Ramesh B, Iannelli A, Staccini-Myx A, Casanova D, Ben Amor I, Saint-Paul M-C, Huet P-M, Sadoul J-L, Gugenheim J, Srail SKS, Tran A, Le Marchand-Brustel Y Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH, *Gastroenterology.* 2006; 131:788–796
28. Jehn M, Clark JM, Guallar E Serum ferritin and risk of the metabolic syndrome in U.S. adults, *Diabetes Care.* 2004; 27:2422–2428
29. Seeßle J, Gan-Schreier H, Kirchner M, Stremmel W, Chamulitrat W, Merle U Plasma Lipidome, PNPLA3 polymorphism and hepatic steatosis in hereditary hemochromatosis, *BMC Gastroenterol.* 2020; 20:230
30. Wilman HR, Parisinos CA, Atabaki-Pasdar N, Kelly M, Thomas EL, Neubauer S, Mahajan A, Hingorani AD, Patel RS, Hemingway H, Franks PW, Bell JD, Banerjee R, Yaghootkar H Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration, *J Hepatol.* 2019; 71:594–602
31. Yuan S, Carter P, Vithayathil M, Kar S, Giovannucci E, Mason AM, Burgess S, Larsson SC Iron Status and Cancer Risk in UK Biobank: A Two-Sample Mendelian Randomization Study, *Nutrients.* 2020; 12
32. Meidtner K, Podmore C, Kröger J, van der Schouw YT, Bendinelli B, Agnoli C, Arriola L, Barricarte A, Boeing H, Cross AJ, Dow C, Ekblom K, Fagherazzi G, Franks PW, Gunter MJ, Huerta JM, Jakszyn P, Jenab M, Katzke VA, Key TJ, Khaw KT, Kühn T, Kyrø C, Mancini FR, Melander O, Nilsson PM, Overvad K, Palli D, Panico S, Quirós JR,

- Rodríguez-Barranco M, Sacerdote C, Sluijs I, Stepien M, Tjonneland A, Tumino R, Forouhi NG, Sharp SJ, Langenberg C, Schulze MB, Riboli E, Wareham NJ Interaction of Dietary and Genetic Factors Influencing Body Iron Status and Risk of Type 2 Diabetes Within the EPIC-InterAct Study, *Diabetes Care*. 2018; 41:277–285
33. Raffield LM, Louie T, Sofer T, Jain D, Ipp E, Taylor KD, Papanicolaou GJ, Avilés-Santa L, Lange LA, Laurie CC, Conomos MP, Thornton TA, Chen Y-DI, Qi Q, Cotler S, Thyagarajan B, Schneiderman N, Rotter JI, Reiner AP, Lin HJ Genome-wide association study of iron traits and relation to diabetes in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL): potential genomic intersection of iron and glucose regulation?, *Hum Mol Genet*. 2017; 26:1966–1978
  34. Tayrac M de, Roth M-P, Jouanolle A-M, Coppin H, Le Gac G, Piperno A, Férec C, Pelucchi S, Scotet V, Bardou-Jacquet E, Ropert M, Bouvet R, Génin E, Mosser J, Deugnier Y Genome-wide association study identifies TF as a significant modifier gene of iron metabolism in HFE hemochromatosis, *J Hepatol*. 2015; 62:664–672
  35. Pitchika A, Kühn J-P, Schipf S, Nauck M, Dörr M, Lerch MM, Kromrey M-L, Felix SB, Markus MRP, Rathmann W, Völzke H, Ittermann T Hepatic steatosis and hepatic iron overload modify the association of iron markers with glucose metabolism disorders and metabolic syndrome, *Liver Int*. 2021; 41:1841–1852
  36. Sharifi F, Nasab NM, Zadeh HJ Elevated serum ferritin concentrations in prediabetic subjects, *Diab Vasc Dis Res*. 2008; 5:15–18
  37. Fillebeen C, Lam NH, Chow S, Botta A, Sweeney G, Pantopoulos K Regulatory Connections between Iron and Glucose Metabolism, *Int J Mol Sci*. 2020; 21
  38. Simcox JA, McClain DA Iron and Diabetes Risk, *Cell Metab*. 2013; 17:329–341
  39. Haap M, Machann J, Friedeburg C von, Schick F, Stefan N, Schwenzer NF, Fritsche A, Häring HU, Thamer C Insulin sensitivity and liver fat: role of iron load, *J Clin Endocrinol Metab*. 2011; 96:E958-61
  40. Bayerl C, Lorbeer R, Heier M, Meisinger C, Rospleszcz S, Schafnitzel A, Patscheider H, Auweter S, Peters A, Ertl-Wagner B, Reiser M, Bamberg F, Hetterich H Alcohol consumption, but not smoking is associated with higher MR-derived liver fat in an asymptomatic study population, *PLoS ONE*. 2018; 13:e0192448
  41. Whitfield JB, Zhu G, Heath AC, Powell LW, Martin NG Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers, *Alcohol Clin Exp Res*. 2001; 25:1037–1045
  42. Bridle K, Cheung T-K, Murphy T, Walters M, Anderson G, Crawford DG, Fletcher LM Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease, *Alcohol Clin Exp Res*. 2006; 30:106–112
  43. Li X, He T, Yu K, Lu Q, Alkasir R, Guo G, Xue Y Markers of Iron Status Are Associated with Risk of Hyperuricemia among Chinese Adults: Nationwide Population-Based Study, *Nutrients*. 2018; 10
  44. Mainous AG, Knoll ME, Everett CJ, Matheson EM, Hulihan MM, Grant AM Uric acid as a potential cue to screen for iron overload, *J Am Board Fam Med*. 2011; 24:415–421
  45. Rospleszcz S, Dermyski D, Müller-Peltzer K, Strauch K, Bamberg F, Peters A Association of serum uric acid with visceral, subcutaneous and hepatic fat quantified by magnetic resonance imaging, *Sci Rep*. 2020; 10:442
  46. Kim BJ, Kim BS, Kang JH The association between serum ferritin level, microalbuminuria and non-alcoholic fatty liver disease in non-diabetic, non-hypertensive men, *Clin Exp Hypertens*. 2014; 36:380–385
  47. Małyszko J, Koc-Żórawska E, Levin-Iaina N, Małyszko J, Koźmiński P, Kobus G, Myśliwiec M New parameters in iron metabolism and functional iron deficiency in patients on maintenance hemodialysis, *Polish Archives of Internal Medicine*. 2012; 122:537–542
  48. Pietrangelo A, Dierssen U, Valli L, Garuti C, Rump A, Corradini E, Ernst M, Klein C, Trautwein C STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo, *Gastroenterology*. 2007; 132:294–300

49. Muckenthaler MU, Rivella S, Hentze MW, Galy B A Red Carpet for Iron Metabolism, *Cell*. 2017; 168:344–361
50. Cheong J-W, Kim H-J, Lee K-H, Yoon S-S, Lee JH, Park H-S, Kim HY, Shim H, Seong C-M, Kim CS, Chung J, Hyun MS, Jo D-Y, Jung CW, Sohn SK, Yoon H-J, Kim BS, Joo Y-D, Park C-Y, Min YH Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia, *Transfusion*. 2014; 54:1542–1551
51. Chatterjee R, Yeh H-C, Edelman D, Brancati F Potassium and risk of Type 2 diabetes, *Expert Rev Endocrinol Metab*. 2011; 6:665–672
52. Angeli P, Wong F, Watson H, Ginès P Hyponatremia in cirrhosis: Results of a patient population survey, *Hepatology*. 2006; 44:1535–1542
53. Mainous AG, Weinberg ED, Diaz VA, Johnson SP, Hulihan MM, Grant AM Calcium channel blocker use and serum ferritin in adults with hypertension, *Biomaterials*. 2012; 25:563–568
54. Zhang Y, Zhao X, Chang Y, Zhang Y, Chu X, Zhang X, Liu Z, Guo H, Wang N, Gao Y, Zhang J, Chu L Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis, *Toxicol Appl Pharmacol*. 2016; 301:50–60

**Table 1:** Descriptive characteristics of the study participants by sex.

	<b>Men (N = 206)</b>	<b>Women (N = 147)</b>	<b>Total (N = 353)</b>	<b>p-value<sup>a</sup></b>
Age (years)	56.0 ± 9.3	56.1 ± 9.0	56.0 ± 9.1	0.928
<b>Body composition</b>				
Body weight (kg)	89.2 ± 13.4	72.4 ± 14.1	82.2 ± 16.0	<0.001
Height (cm)	178.01 ± 6.66	163.68 ± 6.58	172.04 ± 9.68	<0.001
BMI (kg/m <sup>2</sup> )	28.2 ± 4.1	27.1 ± 5.2	27.7 ± 4.7	0.026
Waist circumference (cm)	102.7 ± 11.6	90.5 ± 13.4	97.6 ± 13.7	<0.001
Hip circumference (cm)	106.5 ± 7.1	105.9 ± 10.0	106.3 ± 8.5	0.483
Subcutaneous fat (l)	7.36 ± 3.23	8.72 ± 3.90	7.93 ± 3.58	<0.001
Visceral fat (l)	5.56 ± 2.56	2.79 ± 1.97	4.41 ± 2.70	<0.001
Total fat (l)	12.92 ± 5.26	11.51 ± 5.43	12.34 ± 5.37	0.015
<b>Blood lipids</b>				
Total cholesterol (mg/dl)	217.5 ± 38.1	218.9 ± 34.7	218.1 ± 36.7	0.728
HDL-C (mg/dl)	55.7 ± 14.8	71.1 ± 17.7	62.1 ± 17.7	<0.001
LDL-C (mg/dl)	142.2 ± 33.9	136.3 ± 32.2	139.7 ± 33.3	0.103
TG (mg/dl)	123.0 (100.5)	89.4 (51.0)	105.0 (76.9)	<0.001
<b>Markers of glucose metabolism</b>				
Fasting glucose (mg/dl)	106.9 ± 23.5	98.1 ± 16.5	103.2 ± 21.3	<0.001
Fasting insulin (mU/ml)	11.8 (7.8)	9.3 (5.4)	8.8 (7.4)	<0.001
HbA1c (%)	5.56 ± 0.83	5.51 ± 0.49	5.54 ± 0.71	0.540
2-hour insulin (μU/ml) <sup>b</sup>	46.0 (70.5)	42.0 (39.5)	44.0 (51.8)	0.412
2-hour glucose (mg/dl) <sup>b</sup>	117.4 ± 44.5	104.0 ± 32.9	111.6 ± 40.4	0.003
Diabetes status				0.002
Diabetes	16.0 % (33)	6.8 % (10)	12.2 % (43)	
Prediabetes	26.7 % (55)	19.0 % (28)	23.5 % (83)	
Normoglycemic	57.3 % (118)	74.1 % (109)	64.3 % (227)	
<b>Markers of renal function</b>				
Glomerular filtration rate (ml/min/1.73m <sup>2</sup> )	93.6 ± 16.7	91.2 ± 16.9	92.6 ± 16.8	0.195
Uric acid (mg/dl)	6.33 ± 1.32	4.57 ± 1.11	5.60 ± 1.51	<0.001
Creatinine (mg/dl)	0.96 ± 0.13	0.77 ± 0.12	0.88 ± 0.16	0.001
Albumin (g/dl)	4.41 ± 0.29	4.28 ± 0.27	4.35 ± 0.29	<0.001
Cystatin C (mg/l)	0.89 ± 0.14	0.85 ± 0.17	0.88 ± 0.16	0.029
Urine albumin (mg/l)	6.48 (10.52)	6.22 (8.47)	6.32 (8.85)	0.431
Urine creatinine (g/l)	1.75 ± 0.74	1.39 ± 0.82	1.60 ± 0.79	<0.001
<b>Complete blood count</b>				
Haematocrit (l/l)	0.43 ± 0.03	0.39 ± 0.03	0.42 ± 0.03	<0.001
Thrombocytes (/nl)	221.1 ± 51.6	244.5 ± 52.2	230.9 ± 53.1	<0.001
Erythrocytes (/pl)	4.87 ± 0.37	4.45 ± 0.37	4.70 ± 0.40	<0.001
Leucocytes (/nl)	5.61 (1.93)	5.66 (1.98)	5.65 (1.91)	0.576
Haemoglobin (g/l)	150.4 ± 10.1	134.8 ± 9.8	143.9 ± 12.6	<0.001

<b>Electrolyte panel</b>				
Potassium (mmol/l)	4.32 ± 0.31	4.22 ± 0.22	4.28 ± 0.28	0.001
Sodium (mmol/l)	139.0 (4.0)	139.0 (3.5)	139.0 (4.0)	0.448
Magnesium (mmol/l)	0.85 ± 0.08	0.87 ± 0.08	0.86 ± 0.07	0.062
Phosphate (mmol/l)	0.98 ± 0.13	1.12 ± 0.14	1.04 ± 0.15	<0.001
<b>Blood pressure parameters</b>				
SBP (mmHg)	125.5 ± 16.0	113.0 ± 14.9	120.3 ± 16.4	<0.001
DBP (mmHg)	77.6 ± 10.3	71.8 ± 8.2	75.3 ± 9.9	<0.001
Hypertension	37.4 % (77)	25.9 % (38)	32.6 % (115)	0.025
<b>Liver parameters</b>				
GGT (U/l)	35.3 (33.9)	19.6 (17.5)	27.0 (28.0)	<0.001
AST (U/l)	24.5 (9.0)	20.0 (8.0)	23.0 (9.0)	<0.001
ALT (U/l)	31.0 (15.8)	21.00 (12.0)	27.0 (17.0)	<0.001
Hepatic iron (s <sup>-1</sup> )	41.8 ± 4.7	39.2 ± 4.1	40.7 ± 4.6	<0.001
Right liver lobe (s <sup>-1</sup> )	42.4 ± 5.4	39.7 ± 4.3	41.3 ± 5.2	<0.001
Left liver lobe (s <sup>-1</sup> )	41.1 ± 5.4	38.7 ± 4.7	40.1 ± 5.2	<0.001
Hepatic fat fraction (%)	7.02 (10.08)	3.53 (4.28)	5.38 (7.92)	<0.001
Right liver lobe (%)	7.78 (9.99)	3.96 (4.72)	6.10 (8.99)	<0.001
Left liver lobe (%)	6.39 (10.62)	3.16 (4.34)	4.53 (7.63)	<0.001
<b>Further laboratory values</b>				
Alkaline phosphatase (U/l)	65.9 ± 17.9	67.6 ± 23.6	66.6 ± 20.5	0.448
CRP (mg/l)	1.09 (1.70)	1.26 (2.00)	1.12 (1.78)	0.349
Vitamin D (ng/ml)	24.3 ± 11.8	22.2 ± 11.3	23.4 ± 11.6	0.094
Troponin T (pg/ml)	3.55 (5.20)	1.50 (0.77)	1.50 (3.82)	<0.001
<b>Behavioral risk factors</b>				
Alcohol consumption (g/day)	20.1 (36.5)	3.1 (12.8)	8.6 (25.9)	<0.001
Smoking status				0.243
Smoker	19.9% (41)	22.4% (33)	21.0% (74)	
Ex-smoker	46.1% (95)	35.4% (52)	41.6% (147)	
Never-smoker	34.0% (70)	42.2% (62)	37.4% (132)	
Pack years <sup>c</sup>	17.8 (28.7)	10.9 (17.0)	15.2 (23.2)	<0.001
Physical activity				0.046
Active	55.3% (114)	66.0% (97)	59.8% (211)	
Inactive	44. % (92)	34.0% (50)	40.2% (142)	
<b>Medication intake</b>				
Beta-blockers	11.7% (24)	11.6% (17)	11.6% (41)	1.000
ACE inhibitors	8.7% (18)	13.6% (20)	10.8% (38)	0.169
Calcium antagonists	6.8% (14)	7.5% (11)	7.1% (25)	0.822
Diuretics	11.7% (24)	13.6% (20)	12.5% (44)	0.620
Antihypertensives	23.3% (48)	25.2% (37)	24.1% (85)	0.709
Lipid-lowering agents	10.2% (21)	10.2% (15)	10.2% (36)	1.000
Treatment of hyperuricemia	4.4% (9)	0% (0)	2.5% (9)	0.012

Values are given as arithmetic means ± standard deviation or median (IQR). Categorical variables are given as percentages (counts).

<sup>a</sup>p-values are from t-test or Mann-Whitney-U Test, and X<sup>2</sup> Test, respectively.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP, c-reactive protein; HFF, hepatic fat fraction.

<sup>b</sup>Considering only participants with 2-hour insulin/-glucose data from OGTT (N=323, 184 men, 139 women).

<sup>c</sup>Considering only ex-smokers and current smokers with available data (N=213, 130 men, 83 women).



**Table 2:** Men: Results from unpenalized linear regression analyses.  $\beta$  denotes the regression coefficient of the respective variable for outcome HIC. Adjusted  $R^2$  denotes the variance of HIC explained. Presented are only variables with an inclusion frequency >20% in the variable selection procedure.

	Adjustment	$\beta$	95% CI	p-value	adjusted $R^2$
<b>Blood lipids</b>					
(log) triglycerides (mg/dl)	age + HFF	0.25	-0.94 ; 1.44	0.68	0.08
	age	1.11	-0.01 ; 2.22	0.05	0.03
<b>Markers of glucose metabolism</b>					
(log) fasting insulin (mU/ml)	age + HFF	-0.42	-1.73 ; 0.9	0.53	0.08
	age	0.97	-0.14 ; 2.07	0.09	0.02
HbA1c (%)	age + HFF	-1.44	-2.17 ; -0.71	0.00	0.14
	age	-1.11	-1.87 ; -0.36	0.00	0.05
Prediabetes	age + HFF	0.92	-0.67 ; 2.5	0.25	0.11
	age	2.13	0.64 ; 3.63	0.01	0.05
<b>Markers of renal function</b>					
Uric acid (mg/dl)	age + HFF	0.23	-0.27 ; 0.72	0.37	0.08
	age	0.49	0.01 ; 0.97	0.05	0.03
(log) urine albumin (mg/l)	age + HFF	-0.80	-1.29 ; -0.31	0.00	0.12
	age	-0.69	-1.2 ; -0.19	0.01	0.04
<b>Complete blood count</b>					
Thrombocytes (/nl)	age + HFF	-0.01	-0.02 ; 0.01	0.38	0.08
	age	-0.01	-0.02 ; 0	0.20	0.02
Erythrocytes (/pl)	age + HFF	-1.35	-3.05 ; 0.35	0.12	0.09
	age	-1.03	-2.79 ; 0.73	0.25	0.02
<b>Blood pressure</b>					
Systolic blood pressure (mmHg)	age + HFF	0.01	-0.03 ; 0.06	0.48	0.08
	age	0.04	0 ; 0.08	0.05	0.03
Diastolic blood pressure (mmHg)	age + HFF	0.04	-0.02 ; 0.11	0.17	0.09
	age	0.08	0.02 ; 0.14	0.01	0.04
<b>Liver parameters</b>					
(log) hepatic fat fraction (%)	age	1.46	0.74 ; 2.19	0.00	0.08
<b>Behavioral risk factors</b>					
Alcohol consumption (g/day)	age + HFF	0.02	0 ; 0.05	0.04	0.10
	age	0.03	0.01 ; 0.05	0.01	0.04
<b>Medication intake</b>					
ACE inhibitors	age + HFF	-3.61	-5.79 ; -1.43	0.00	0.12
	age	-2.78	-5.03 ; -0.53	0.02	0.04
Diuretics	age + HFF	-2.50	-4.44 ; -0.56	0.01	0.11
	age	-1.97	-3.97 ; 0.04	0.05	0.03
<b>Genetic analyses (N=195)</b>					
Genetic risk score, continuous	age + HFF	0.64	0.16 ; 1.12	0.01	0.12


CI, confidence interval; HFF, hepatic fat fraction.

**Table 3:** Women: Results from unpenalized linear regression analyses.  $\beta$  denotes the regression coefficient of the respective variable for outcome HIC. Adjusted  $R^2$  denotes the variance of HIC explained. Presented are only variables with an inclusion frequency >20% in the variable selection procedure.


	Adjustment	$\beta$	95% CI	p-value	adjusted $R^2$
<b>Body composition</b>					
Height (cm)	age + HFF	-0.04	-0.13 ; 0.05	0.40	0.36
	age	-0.05	-0.15 ; 0.05	0.29	0.21
Visceral fat (l)	age + HFF	0.01	-0.12 ; 0.14	0.91	0.35
	age	0.81	0.5 ; 1.13	0.00	0.33
<b>Blood lipid markers</b>					
(log) triglycerides (mg/dl)	age + HFF	-0.20	-1.8 ; 1.4	0.81	0.35
	age	1.70	0.14 ; 3.26	0.03	0.23
<b>Markers of glucose metabolism</b>					
Fasting glucose (mg/dl)	age + HFF	0.01	-0.02 ; 0.05	0.47	0.36
	age	0.05	0.01 ; 0.09	0.01	0.24
<b>Markers of renal function</b>					
Urine creatinine (g/l)	age + HFF	-0.47	-1.14 ; 0.21	0.17	0.36
	age	-0.14	-0.89 ; 0.6	0.70	0.21
<b>Complete blood count</b>					
Thrombocytes (/nl)	age + HFF	0.01	-0.01 ; 0.02	0.34	0.36
	age	0.00	-0.01 ; 0.01	0.71	0.21
Erythrocytes (/pl)	age + HFF	-1.24	-3.02 ; 0.55	0.17	0.36
	age	-0.91	-2.9 ; 1.07	0.36	0.21
<b>Electrolyte panel</b>					
Potassium (mmol/l)	age + HFF	-2.74	-5.13 ; -0.34	0.03	0.38
	age	-2.44	-5.11 ; 0.22	0.07	0.22
(log) sodium (mmol/l)	age + HFF	-19.63	-45.67 ; 6.4	0.14	0.36
	age	-40.47	-67.31 ; -13.63	0.00	0.25
Phosphate (mmol/l)	age + HFF	2.62	-1.51 ; 6.76	0.21	0.36
	age	0.61	-3.94 ; 5.15	0.79	0.21
<b>Liver parameters</b>					
(log) hepatic fat fraction (%)	age	2.08	1.38 ; 2.79	0.00	0.36
<b>Further laboratory values</b>					
Vitamin D (ng/ml)	age + HFF	-0.02	-0.07 ; 0.03	0.46	0.36
	age	-0.04	-0.1 ; 0.01	0.10	0.22
<b>Behavioral risk factors</b>					
Alcohol consumption (g/day)	age + HFF	0.05	0.02 ; 0.09	0.00	0.39
	age	0.07	0.03 ; 0.11	0.00	0.26
<b>Medication intake</b>					
Beta-blockers	age + HFF	0.31	-1.53 ; 2.15	0.74	0.35
	age	1.69	-0.26 ; 3.63	0.09	0.22
Calcium antagonists	age + HFF	-2.24	-4.29 ; -0.19	0.03	0.37

	age	-2.35	-4.63 ; -0.07	0.04	0.23
Lipid-lowering agents	age + HFF	1.19	-0.67 ; 3.06	0.21	0.36
	age	1.89	-0.14 ; 3.93	0.07	0.22
<b>Genetic analyses (N=132)</b>					
Genetic risk score, continuous	age + HFF	0.65	0.16; 1.14	0.01	0.39



CI, confidence interval; HFF, hepatic fat fraction.




**Figure 1:** Participant flow chart. MRI, magnetic resonance imaging; CAD, coronary artery disease; MI, myocardial infarction; PAD, peripheral artery disease; ICD, implantable cardioverter defibrillator.



**Figure 2:** Scatter plots showing the sex-specific correlations of HIC with a) age and b) HFF, respectively. Lines denote the regression lines derived from locally weighted smoothing. Rho denotes the Spearman's rank correlation coefficients.




**Figure 3:** Boxplots of HIC according to genetic risk score quartiles for a) men and b) women.



**Figure 4:** Bar diagrams of results from the model including HFF for a) men and b) women. Relevant variables were identified by variable selection through LASSO regression on 1000 bootstrap samples. On the y-axis: Inclusion frequency of the respective variable across 1000 bootstrap samples. Presented are only variables with an inclusion frequency > 20%.





**Figure 5:** Bar diagrams of results from the model including genetic risk score for a) men and b) women. Relevant variables were identified by variable selection through LASSO regression on 1000 bootstrap samples. On the y-axis: Inclusion frequency of the respective variable across 1000 bootstrap samples. Presented are only variables with an inclusion frequency > 20%.